Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
77.09(c) 78.95(c) 77.5(c) 79.81(c) 79.25(c) Last
170 522 148 546 148 228 159 808 97 930 Volume
+0.72% +2.41% -1.84% +2.98% -0.70% Change
More quotes
Financials (€)
Sales 2017 55,4 M
EBIT 2017 -54,0 M
Net income 2017 -64,9 M
Finance 2017 270 M
Yield 2017 -
Sales 2018 53,2 M
EBIT 2018 -58,5 M
Net income 2018 -67,0 M
Finance 2018 226 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 37,1x
EV / Sales2018 39,5x
Capitalization 2 327 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery and Proprietary Development.The Partnered Discovery segment involves technologies for the generation of human antibody... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
11/14 MORPHOSYS AG : Release according to Article 26, Section 1 of the WpHG [the Germa..
11/10 MORPHOSYS : Announces Third Quarter 2017 Results
11/07 MORPHOSYS AG : Sponsored ADR to Host Earnings Call
11/07 MORPHOSYS : Announces Third Quarter 2017 Results
11/07 MORPHOSYS : Announces Third Quarter 2017 Results
11/06 MORPHOSYS : Announces Presentation of Clinical Data on Proprietary Blood Cancer ..
11/02MORPHOSYS AG : quaterly earnings release
11/02 MORPHOSYS : Announces Presentation of Clinical Data on Proprietary Blood Cancer ..
11/02 MORPHOSYS : Announces Presentation of Clinical Data on Proprietary Blood Cancer ..
10/30 MORPHOSYS AG : Release according to Article 26a of the WpHG [the German Securiti..
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/07 Morphosys' (MPSYF) CEO Simon Moroney on Q3 2017 Results - Earnings Call Trans..
11/07 MorphoSys AG 2017 Q3 - Results - Earnings Call Slides
11/07 MorphoSys AG reports Q3 results
09/28 Why Celldex Therapeutics Is A Buy (Part 2)
09/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 22, 2017
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 80,9 €
Spread / Average Target 2,1%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Günter Wellnhofer Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG62.56%2 743
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.52%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538